IBI3013 / Innovent Biologics - LARVOL DELTA

Development and Characterization of IBI3013, a Novel Half-life Extended Monoclonal Antibody Targeting Interleukin-15 (IL-15) (EADV 2025) - "In summary, we developed a potent and half-life extended IL-15 mAb with potential as an effective, safe, and convenient treatment for patients with vitiligo and other IL-15 driving autoimmune diseases, including alopecia areata and celiac disease."

Alopecia • Celiac Disease • Dermatitis • Dermatology • Graft versus Host Disease • Immunology • Inflammation • Vitiligo • CD8 • IFNG • IL15

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025 (PRNewswire) - "Specifically, post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 (IL-23p19 monoclonal antibody, picankibart), as well as preclinical study results of IBI3013 (IL-15 monoclonal antibody) and IAR129 (IL-4R/OX40L bispecific antibody) will be showcased via ePoster."

Clinical data • Preclinical • Atopic Dermatitis • Psoriasis